The FinancialContent Network     SocialPicks Community   |   MarketMinute Monitor   |   MarketMinute Market Updates   |   MarketMinute Stock News
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     

MannKind: Speculation on inhaled insulin

 Jul 06, 2009 08:40 PM UTC
Return Risk
+4.73% MID
Tracked Blogger
Symbol Sentiment Start Return Closed
MNKD Positive 07/06/09 -14.11% --

Graphic_arrow1 Via BloggingStocks:  

Filed under: Newsletters, Stocks to Buy

"In looking for a highly speculative stock for our portfolio, I have settled on MannKind Corp. (NASDAQ: MNKD), a company that is developing an inhaled insulin product," says Nate Pile.


In his growth-oriented Nate's Notes, the advisor cautions, "I believe we are looking at a situation in which we will either lose most of our money, or triple (or better) our investment in a fairly short period of time."


"In a nutshell, the company's near-term fate hinges upon AFRESA, a novel, ultra rapid acting mealtime insulin therapy being studied for use in adult patients with type 1 and type 2 diabetes mellitus for the treatment of hyperglycemia.


"Working against the company is the fact that there has never been an inhaled insulin product approved for commercial use that has worked very well.

Continue reading MannKind: Speculation on inhaled insulin

MannKind: Speculation on inhaled insulin originally appeared on BloggingStocks on Mon, 06 Jul 2009 15:40:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments



Add to digg
Add to del.icio.us
Add to Google
Add to StumbleUpon
Add to Facebook
Add to Reddit
Add to Technorati



 Graphic_website1 Read the rest of original post »



Add Comment

Be the first to comment on this story and earn 2 points.

Your Comment



IN THE PRESS
Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch